ES2701089T3 - Uso terapéutico de las diaminofenotiazinas - Google Patents
Uso terapéutico de las diaminofenotiazinas Download PDFInfo
- Publication number
- ES2701089T3 ES2701089T3 ES15161198T ES15161198T ES2701089T3 ES 2701089 T3 ES2701089 T3 ES 2701089T3 ES 15161198 T ES15161198 T ES 15161198T ES 15161198 T ES15161198 T ES 15161198T ES 2701089 T3 ES2701089 T3 ES 2701089T3
- Authority
- ES
- Spain
- Prior art keywords
- unsubstituted
- substituted
- aliphatic
- carboaryl
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US96054407P | 2007-10-03 | 2007-10-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2701089T3 true ES2701089T3 (es) | 2019-02-20 |
Family
ID=40220337
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES15161198T Active ES2701089T3 (es) | 2007-10-03 | 2008-10-01 | Uso terapéutico de las diaminofenotiazinas |
| ES08806465.4T Active ES2546819T3 (es) | 2007-10-03 | 2008-10-01 | Uso terapéutico de las diaminofenotiazinas |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES08806465.4T Active ES2546819T3 (es) | 2007-10-03 | 2008-10-01 | Uso terapéutico de las diaminofenotiazinas |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US9149481B2 (https=) |
| EP (2) | EP2205245B1 (https=) |
| JP (1) | JP5592261B2 (https=) |
| CN (1) | CN101883567B (https=) |
| AU (1) | AU2008306688B2 (https=) |
| BR (1) | BRPI0818182B1 (https=) |
| CA (2) | CA3027974C (https=) |
| DK (2) | DK2954932T3 (https=) |
| ES (2) | ES2701089T3 (https=) |
| HR (1) | HRP20151006T1 (https=) |
| HU (1) | HUE025199T2 (https=) |
| MY (1) | MY161656A (https=) |
| PL (2) | PL2954932T3 (https=) |
| PT (2) | PT2954932T (https=) |
| SI (2) | SI2205245T1 (https=) |
| WO (1) | WO2009044127A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2013191B3 (en) | 2006-03-29 | 2019-02-27 | Wista Laboratories Ltd. | 3,7-diamino-10h-phenothiazine salts and their use |
| CA3027974C (en) * | 2007-10-03 | 2022-03-15 | Wista Laboratories Ltd. | Therapeutic use of diaminophenothiazines |
| CN102958525B (zh) | 2010-04-30 | 2017-05-24 | 普罗瑟塔抗病毒股份有限公司 | 抗病毒化合物 |
| US8828986B2 (en) | 2011-04-20 | 2014-09-09 | Prosetta Antiviral Inc. | Antiviral compounds |
| US9192611B2 (en) | 2010-11-30 | 2015-11-24 | Wista Laboratories Ltd. | Formulations comprising methylthioninium chloride |
| US8703137B2 (en) | 2011-01-31 | 2014-04-22 | Intellect Neurosciences Inc. | Treatment of tauopathies |
| EA025033B1 (ru) * | 2011-02-11 | 2016-11-30 | Уиста Лэборэтэриз Лтд. | Диаминиевые соли фенотиазина и их применение |
| CN102690244A (zh) * | 2011-03-22 | 2012-09-26 | 中国科学院上海生命科学研究院 | 调节α-突触核蛋白积聚的物质及其制药用途 |
| US20130315825A1 (en) * | 2012-05-03 | 2013-11-28 | Washington University | Tricyclic heteroaromatic compounds as alpha-synuclein ligands |
| CN103864717B (zh) * | 2014-04-04 | 2015-11-11 | 山东理工大学 | 一种针状亚甲基白晶体的制备方法 |
| CN103923036B (zh) * | 2014-04-24 | 2015-09-16 | 山东理工大学 | 一种棒状亚甲基蓝晶体的制备方法 |
| CN105541756B (zh) * | 2015-12-17 | 2018-02-09 | 陕西方舟制药有限公司 | 一种制备1‑(3，7‑双二甲氨基‑吩噻嗪‑10‑基)乙酮的方法 |
| KR102592614B1 (ko) | 2016-07-25 | 2023-10-24 | 위스타 레보레이토리스 리미티드 | 디아미노페노티아진 (diaminophenothiazines)의 투여 및 투여량 (dosage) |
| GB201614834D0 (en) * | 2016-09-01 | 2016-10-19 | Wista Lab Ltd | Treatment of dementia |
| DK3826639T3 (da) | 2018-07-26 | 2024-09-23 | Wista Lab Ltd | Optimeret dosering af diaminophenothiaziner i populationer |
| WO2020201828A1 (en) | 2019-04-05 | 2020-10-08 | Tauc3 Biologics Limited | Anti-tauc3 antibodies and uses thereof |
| GB201909454D0 (en) | 2019-07-01 | 2019-08-14 | Wista Lab Ltd | Enhancers |
| GB201909493D0 (en) | 2019-07-01 | 2019-08-14 | Wista Lab Ltd | Therapeutic interactions |
| GB201909506D0 (en) | 2019-07-02 | 2019-08-14 | Wista Lab Ltd | Synaptopathies |
| CN111956245A (zh) * | 2020-08-27 | 2020-11-20 | 复旦大学附属肿瘤医院 | 术后认知功能障碍预防评估方法，系统和装置 |
| WO2023232764A1 (en) | 2022-05-31 | 2023-12-07 | Wista Laboratories Ltd. | Treatment of neurodegenerative disorders utilising methylthioninium (mt)-containing compounds |
| AU2023346900A1 (en) | 2022-09-21 | 2025-04-10 | TauRx Therapeutics Management Ltd | Novel formulations and vehicles |
| WO2024163665A1 (en) * | 2023-01-31 | 2024-08-08 | Unlearn.AI, Inc. | Systems and methods for prognostic covariate adjustment in logistic regression for randomized controlled trial design |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9022788D0 (en) * | 1990-10-19 | 1990-12-05 | Cortecs Ltd | Pharmaceutical formulations |
| DE4140192C2 (de) * | 1991-12-05 | 1996-02-29 | Alfatec Pharma Gmbh | Sol-gesteuerte Thermokolloidmatrix auf Gelatinebasis für perorale Retardformen |
| GB9506197D0 (en) * | 1995-03-27 | 1995-05-17 | Hoffmann La Roche | Inhibition of tau-tau association. |
| US5972389A (en) | 1996-09-19 | 1999-10-26 | Depomed, Inc. | Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter |
| GB9710699D0 (en) | 1997-05-24 | 1997-07-16 | Danbiosyst Uk | Gastro-retentive controlled release system |
| GB0017060D0 (en) * | 2000-07-11 | 2000-08-30 | Hunter Fleming Ltd | Production, stabilisation and use of reduced forms of pharmaceutical compounds |
| GB0100119D0 (en) * | 2001-01-03 | 2001-02-14 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
| GB0101049D0 (en) * | 2001-01-15 | 2001-02-28 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
| GB0106953D0 (en) | 2001-03-20 | 2001-05-09 | Univ Aberdeen | Neufofibrillary labels |
| US7410965B2 (en) * | 2002-05-29 | 2008-08-12 | Gruenenthal Gmbh | Delayed release pharmaceutical composition containing 1-dimethyl-amino-3-(3-methoxyphenyl)-2-methyl-pentan-3-ol |
| GB0322756D0 (en) | 2003-09-29 | 2003-10-29 | Univ Aberdeen | Methods of chemical synthesis |
| CN101084204B (zh) * | 2004-09-23 | 2012-12-05 | 卫思道制药有限公司 | 包括亚甲蓝(mtc)在内的二氨基吩噻嗪鎓化合物的化学合成和纯化方法 |
| WO2006091728A2 (en) * | 2005-02-24 | 2006-08-31 | The Trustees Of The University Of Pennsylvania | Microtubule stabilizing compounds and methods of their use |
| US20070116757A1 (en) | 2005-11-08 | 2007-05-24 | Collegium Pharmaceutical, Inc. | Methylene Blue Derivatives |
| PL2004155T3 (pl) * | 2006-03-29 | 2018-08-31 | Wista Laboratories Ltd. | Inhibitory agregacji białek |
| EP2013191B3 (en) * | 2006-03-29 | 2019-02-27 | Wista Laboratories Ltd. | 3,7-diamino-10h-phenothiazine salts and their use |
| DK3121169T3 (da) * | 2006-07-11 | 2022-02-28 | Wista Lab Ltd | Fremgangsmåder til syntese og/eller oprensning af diaminophenothiaziniumforbindelser |
| CN101820884B (zh) * | 2007-06-19 | 2013-08-28 | 维斯塔实验室有限公司 | 用于治疗轻度认知缺损的吩噻嗪化合物 |
| CA3027974C (en) * | 2007-10-03 | 2022-03-15 | Wista Laboratories Ltd. | Therapeutic use of diaminophenothiazines |
-
2008
- 2008-10-01 CA CA3027974A patent/CA3027974C/en active Active
- 2008-10-01 DK DK15161198.5T patent/DK2954932T3/en active
- 2008-10-01 DK DK08806465.4T patent/DK2205245T3/en active
- 2008-10-01 PL PL15161198T patent/PL2954932T3/pl unknown
- 2008-10-01 ES ES15161198T patent/ES2701089T3/es active Active
- 2008-10-01 SI SI200831497T patent/SI2205245T1/sl unknown
- 2008-10-01 JP JP2010527519A patent/JP5592261B2/ja active Active
- 2008-10-01 CN CN2008801190788A patent/CN101883567B/zh active Active
- 2008-10-01 MY MYPI2010001396A patent/MY161656A/en unknown
- 2008-10-01 WO PCT/GB2008/003315 patent/WO2009044127A1/en not_active Ceased
- 2008-10-01 BR BRPI0818182-9A patent/BRPI0818182B1/pt active IP Right Grant
- 2008-10-01 HU HUE08806465A patent/HUE025199T2/en unknown
- 2008-10-01 EP EP08806465.4A patent/EP2205245B1/en active Active
- 2008-10-01 ES ES08806465.4T patent/ES2546819T3/es active Active
- 2008-10-01 EP EP15161198.5A patent/EP2954932B1/en active Active
- 2008-10-01 HR HRP20151006TT patent/HRP20151006T1/hr unknown
- 2008-10-01 CA CA2701075A patent/CA2701075C/en active Active
- 2008-10-01 US US12/681,511 patent/US9149481B2/en active Active
- 2008-10-01 PT PT15161198T patent/PT2954932T/pt unknown
- 2008-10-01 AU AU2008306688A patent/AU2008306688B2/en active Active
- 2008-10-01 SI SI200832022T patent/SI2954932T1/sl unknown
- 2008-10-01 PL PL08806465T patent/PL2205245T3/pl unknown
- 2008-10-01 PT PT88064654T patent/PT2205245E/pt unknown
-
2015
- 2015-09-25 US US14/866,035 patent/US10188658B2/en active Active
-
2019
- 2019-01-15 US US16/248,746 patent/US20190151329A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2701089T3 (es) | Uso terapéutico de las diaminofenotiazinas | |
| ES2946165T3 (es) | Administración y dosificación de diaminofenotiazinas | |
| ES2989458T3 (es) | Dosis optimizada de diaminofenotiazinas en poblaciones | |
| ES2739546T3 (es) | Compuestos de fenotiazina para tratar el deterioro cognitivo leve | |
| HK1211889B (en) | Therapeutic use of diaminophenothiazines | |
| HK1140675B (en) | Therapeutic use of diaminophenothiazines | |
| TW202410901A (zh) | 利用含亞甲藍(mt)化合物治療神經退化性疾病 | |
| HK40106579B (en) | Administration and dosage of diaminophenothiazines |